4.1 Article

Modeling of Functional Assessment Questionnaire (FAQ) as continuous bounded data from the ADNI database

Journal

JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Volume 39, Issue 6, Pages 601-618

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10928-012-9271-3

Keywords

Bounded outcome data; Disease progression; Alzheimer's disease; ADNI

Funding

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
  3. Abbott
  4. Alzheimer's Association
  5. Alzheimer's Drug Discovery Foundation
  6. Amorfix Life Sciences Ltd.
  7. AstraZeneca
  8. Bayer HealthCare
  9. BioClinica, Inc.
  10. Biogen Idec Inc.
  11. Bristol-Myers Squibb Company
  12. Eisai Inc.
  13. Elan Pharmaceuticals Inc.
  14. Eli Lilly and Company
  15. F. Hoffmann-La Roche Ltd
  16. Genentech, Inc.
  17. GE Healthcare
  18. Innogenetics, N.V.
  19. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  20. Johnson & Johnson Pharmaceutical Research & Development LLC.
  21. Medpace, Inc.
  22. Merck Co., Inc.
  23. Meso Scale Diagnostics, LLC.
  24. Novartis Pharmaceuticals Corporation
  25. Pfizer Inc.
  26. Servier
  27. Synarc Inc.
  28. Takeda Pharmaceutical Company
  29. Canadian Institutes of Health Research
  30. NIH [P30 AG010129, K01 AG030514]
  31. Dana Foundation

Ask authors/readers for more resources

An assessment of abilities to function independently in daily life is an important clinical endpoint for all Alzheimer's disease (AD) patients and caregivers. A mathematical model was developed to describe the natural history of change of the Functional Assessment Questionnaire (FAQ) from data obtained in normal elderly, mild cognitive impairment, and mild AD in the AD neuroimaging initiative (ADNI) study. FAQ is a bounded outcome (ranging from 0 to 30), with 0 scored as no impairment and 30 as severely impaired. Since many normal elderly patients had 0 scores and some AD patients had scores of 30 in the ADNI database, a censored approach for handling the boundary data was compared with a standard approach, which ignores the bounded nature of the data. Baseline severity, ApoE4 genotype, age, sex, and imaging biomarkers were tested as covariates. The censored approach greatly improved the predictability of the disease progression in FAQ scores. The basic method for handling boundary data used in this analysis is also applicable to handle boundary observations for numerous other endpoints.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available